Insider Transactions in Q4 2025 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
51,726
-0.67%
|
$3,569,094
$69.01 P/Share
|
|
Dec 29
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,726
+0.67%
|
$310,356
$6.15 P/Share
|
|
Dec 26
2025
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
7,530
-9.83%
|
$527,100
$70.0 P/Share
|
|
Dec 22
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,586
-0.16%
|
$855,848
$68.59 P/Share
|
|
Dec 19
2025
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
10,000
-8.17%
|
$670,000
$67.74 P/Share
|
|
Dec 19
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,445
-0.12%
|
$900,815
$67.72 P/Share
|
|
Dec 19
2025
|
Victoria Vakiener Director |
SELL
Open market or private sale
|
Direct |
10,040
-7.87%
|
$672,680
$67.66 P/Share
|
|
Dec 19
2025
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
8,367
-4.44%
|
$560,589
$67.73 P/Share
|
|
Dec 17
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
85,000
-0.55%
|
$5,440,000
$64.97 P/Share
|
|
Dec 16
2025
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+15.21%
|
-
|
|
Dec 16
2025
|
Douglas S Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+14.47%
|
-
|
|
Dec 16
2025
|
Victoria Vakiener Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+14.59%
|
-
|
|
Dec 16
2025
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+5.97%
|
-
|
|
Dec 16
2025
|
Lu Hongbo Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+12.45%
|
-
|
|
Dec 16
2025
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+9.26%
|
-
|
|
Dec 16
2025
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+10.75%
|
-
|
|
Dec 16
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
54,298
-0.15%
|
$3,475,072
$64.05 P/Share
|
|
Dec 15
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
130,000
-1.06%
|
$8,970,000
$69.3 P/Share
|
|
Dec 12
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,000
+4.2%
|
-
|
|
Dec 05
2025
|
Michael S Perry Director |
SELL
Open market or private sale
|
Direct |
16,250
-12.36%
|
$991,250
$61.03 P/Share
|
|
Nov 28
2025
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
8,750
-11.29%
|
$490,000
$56.39 P/Share
|
|
Oct 01
2025
|
James C Hamilton Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-8.62%
|
$700,000
$35.0 P/Share
|